Jianhe Bio

Jianhe Bio is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of next-generation radiopharmaceuticals for oncology. The company utilizes a proprietary theranostics platform to integrate targeted radionuclide therapy (TRT) with molecular imaging for precision cancer treatment. Its pipeline focuses on high-affinity ligands for validated targets such as PSMA and FAP, optimized for both diagnostic and therapeutic applications. Jianhe Bio's lead candidate, JH001, is currently undergoing clinical evaluation for the treatment of metastatic castration-resistant prostate cancer. Supported by prominent healthcare investors, the company operates state-of-the-art GMP manufacturing facilities to ensure the reliable production and delivery of its radioligand therapies.